

Pacira Pharmaceuticals, Inc.  
Form 8-K  
August 27, 2014

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**  
**Pursuant to Section 13 or 15(d) of the**  
**Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **August 25, 2014**

**PACIRA PHARMACEUTICALS, INC.**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction  
of incorporation)

**001-35060**  
(Commission  
File Number)

**51-0619477**  
(IRS Employer  
Identification No.)

**5 Sylvan Way, Suite 300, Parsippany, New Jersey 07054**

(Address of principal executive offices) (Zip Code)

**(973) 254-3560**

Registrant's telephone number, including area code

## Edgar Filing: Pacira Pharmaceuticals, Inc. - Form 8-K

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 1.01. Entry into a Material Definitive Agreement.**

On August 25, 2014, Pacira Pharmaceuticals, Inc. (the Company) entered into a Second Amendment to Commercial Outsourcing Services Agreement (the Second Amendment) with Integrated Commercialization Solutions, Inc. (ICS), which amends the Commercial Outsourcing Services Agreement originally entered into with ICS on August 25, 2011 (as amended, the Agreement). The Second Amendment extends the term of the Agreement to August 25, 2017 and updates certain pricing terms. The Agreement is otherwise unchanged. Pursuant to the terms of the Agreement, ICS serves as the Company's exclusive third party logistics provider to support the commercialization of EXPAREL® in the United States. The logistics services provided to the Company by ICS include, among other things, customer service support, warehousing and distribution services, contract administration and chargeback processing services, accounts receivable management and cash application services, financial management and information technology services.

The foregoing description of the Second Amendment does not purport to be complete and is qualified in its entirety by the terms of the Second Amendment. The Company will file a copy of the Second Amendment as an exhibit to its Quarterly Report on Form 10-Q for the quarter ending September 30, 2014.

**Signatures**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Pacira Pharmaceuticals, Inc.

Date: August 27, 2014

By:

/s/ James Scibetta

James Scibetta

Senior Vice President and Chief Financial Officer